On October 7, 2026, the FDA approved Rhapsido (remibrutinib) for adults with symptomatic dermographism whose symptoms remain inadequately controlled with H1 antihistamines. As an allergist, I consider this an important development because symptomatic dermographism has historically had remarkably few treatment options. Symptomatic dermographism is a form of chronic inducible urticaria in which scratching, rubbing, pressure […]
Barzolvolimab: A Breakthrough Treatment Being Studied for Cold Urticaria and Symptomatic Dermographism
Patients with chronic hives often struggle with symptoms that appear without warning. For some individuals, however, hives are triggered by very specific physical stimuli. Two common forms of chronic inducible urticaria are cold-induced urticaria and symptomatic dermographism, both of which can significantly affect daily life. A promising new medication called barzolvolimab is currently being studied […]
Rhapsido vs Xolair vs Dupixent for Chronic Hives
Rhapsido vs Xolair vs Dupixent — which targeted treatment is right for chronic hives? Chronic spontaneous urticaria (CSU, “chronic hives”) can be maddening: daily itch, unpredictable wheals, and flares that don’t respond to antihistamines. Over the last few years clinicians have gained new targeted options beyond antihistamines — an injectable anti-IgE (Xolair), an injectable IL-4/13 […]
Rhapsido (remibrutinib) wins FDA approval for chronic hives
The FDA has just approved Rhapsido® (remibrutinib) — the first oral, targeted Bruton tyrosine kinase (BTK) inhibitor authorized for chronic spontaneous urticaria (CSU) in adults who remain symptomatic despite H1-antihistamines. This is a genuinely new treatment class and — importantly — an oral alternative to biologics. Below I summarize the data, how allergists are likely […]
New treatments for chronic hives
New treatments for chronic hives are currently being studied. Chronic urticaria or hives is defined as having urticaria for more than 6 weeks duration. Chronic hives have been called chronic idiopathic urticaria, chronic autoimmune urticaria or chronic spontaneous urticaria. There is also chronic inducible urticaria which can be brought on by cold, delayed pressure, solar, […]
Chronic Hives work up not essential or cost effective
Chronic hives or chronic spontaneous urticaria or chronic idiopathic urticaria or chronic autoimmune urticaria is characterized by moving, itching wheals that occur with variable frequency for 6 weeks duration or more. Stepwise approach to Chronic Urticaria (Chronic Hives) It can occur in adults and pediatrics, but it is more common in adults. It is usually […]
Dupixent for Hives
Dupixent for hives is novel treatment option for patients with difficult to treatment chronic spontaneous urticaria. Chronic hives is a common condition marked by episodes of elevated, itching, red wheals persisting for more than 6 weeks without a specific known cause. It is estimated that chronic hives affects about 1% of the population. The mechanism […]
Mast Cell Activation Syndrome (MCAS): Fact & Fiction
Mast cell activation syndrome (MCAS) is a rare condition defined by a severe systemic reaction to mast cell derived mediators. Mast cells are effector cells of the immune system. These cells produce a variety of proinflammatory mediators and participate in a number of different pathological conditions. In patients the risk of developing severe anaphylactic (hypersensitivity) events […]
Cold Hives (urticaria): A review
Cold hives (or urticaria), is a subtype of physical hives that is characterized by the development of hives and swelling in response to cold exposure and rewarming of the skin. It is related to the histamine release of mast cells. Several studies have shown that it is related to IgE and an unknown skin autoallergen […]
Severe Hives Treatment (Xolair and Cyclosporine)
Severe hives or chronic spontaneous urticaria is classified as hives with or without swelling that occurs for 6 weeks or more with an unknown cause. The prevalence of chronic hives (also known as chronic idiopathic urticaria) is approximately 0.5% to 5% of the population. Chronic hives may be active for 1-5 years at a time, […]








